Zacks Investment Research upgraded shares of ObsEva SA (NASDAQ:OBSV) from a sell rating to a hold rating in a research report sent to investors on Wednesday, July 19th.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
OBSV has been the subject of a number of other reports. Credit Suisse Group reaffirmed an outperform rating and set a $27.00 price objective on shares of ObsEva SA in a report on Tuesday, April 18th. HC Wainwright began coverage on shares of ObsEva SA in a report on Thursday, June 29th. They set a buy rating and a $27.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. ObsEva SA presently has a consensus rating of Buy and an average target price of $24.00.
Shares of ObsEva SA (NASDAQ:OBSV) opened at 7.97 on Wednesday. ObsEva SA has a 12 month low of $5.00 and a 12 month high of $14.69. The firm’s market cap is $212.19 million. The firm’s 50-day moving average price is $7.34 and its 200-day moving average price is $9.28.
ObsEva SA (NASDAQ:OBSV) last issued its quarterly earnings results on Thursday, May 18th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.17. Analysts expect that ObsEva SA will post ($2.04) earnings per share for the current year.
Large investors have recently made changes to their positions in the company. NEA Management Company LLC purchased a new stake in shares of ObsEva SA during the first quarter worth about $34,734,000. Sphera Funds Management LTD. purchased a new stake in shares of ObsEva SA during the first quarter worth about $2,197,000. UBS Oconnor LLC purchased a new stake in shares of ObsEva SA during the first quarter worth about $1,017,000. Citadel Advisors LLC purchased a new stake in shares of ObsEva SA during the first quarter worth about $937,000. Finally, Nexthera Capital LP purchased a new stake in shares of ObsEva SA during the first quarter worth about $521,000. Institutional investors and hedge funds own 49.24% of the company’s stock.
About ObsEva SA
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Get a free copy of the Zacks research report on ObsEva SA (OBSV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ObsEva SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva SA and related companies with MarketBeat.com's FREE daily email newsletter.
